Literature DB >> 25953687

Markers of progression in early-stage invasive breast cancer: a predictive immunohistochemical panel algorithm for distant recurrence risk stratification.

Mohammed A Aleskandarany1, D Soria, A R Green, C Nolan, Maria Diez-Rodriguez, I O Ellis, E A Rakha.   

Abstract

Accurate distant metastasis (DM) prediction is critical for risk stratification and effective treatment decisions in breast cancer (BC). Many prognostic markers/models based on tissue marker studies are continually emerging using conventional statistical approaches analysing complex/dimensional data association with DM/poor prognosis. However, few of them have fulfilled satisfactory evidences for clinical application. This study aimed at building DM risk assessment algorithm for BC patients. A well-characterised series of early invasive primary operable BC (n = 1902), with immunohistochemical expression of a panel of biomarkers (n = 31) formed the material of this study. Decision tree algorithm was computed using WEKA software, utilising quantitative biomarkers' expression and the absence/presence of distant metastases. Fifteen biomarkers were significantly associated with DM, with six temporal subgroups characterised based on time to development of DM ranging from <1 to >15 years of follow-up. Of these 15 biomarkers, 10 had a significant expression pattern where Ki67LI, HER2, p53, N-cadherin, P-cadherin, PIK3CA and TOMM34 showed significantly higher expressions with earlier development of DM. In contrast, higher expressions of ER, PR and BCL2 were associated with delayed occurrence of DM. DM prediction algorithm was built utilising cases informative for the 15 significant markers. Four risk groups of patients were characterised. Three markers p53, HER2 and BCL2 predicted the probability of DM, based on software-generated cut-offs, with a precision rate of 81.1 % for positive predictive value and 77.3 %, for the negative predictive value. This algorithm reiterates the reported prognostic values of these three markers and underscores their central biological role in BC progression. Further independent validation of this pruned panel of biomarkers is therefore warranted.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25953687     DOI: 10.1007/s10549-015-3406-3

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  10 in total

1.  P-cadherin: a useful biomarker for axillary-based breast cancer decisions in the clinical practice.

Authors:  André Filipe Vieira; Maria Rita Dionísio; Madalena Gomes; Jorge F Cameselle-Teijeiro; Manuela Lacerda; Isabel Amendoeira; Fernando Schmitt; Joana Paredes
Journal:  Mod Pathol       Date:  2017-01-13       Impact factor: 7.842

2.  Novel Entropically Driven Conformation-specific Interactions with Tomm34 Protein Modulate Hsp70 Protein Folding and ATPase Activities.

Authors:  Michal Durech; Filip Trcka; Petr Man; Elizabeth A Blackburn; Lenka Hernychova; Petra Dvorakova; Dominika Coufalova; Daniel Kavan; Borivoj Vojtesek; Petr Muller
Journal:  Mol Cell Proteomics       Date:  2016-03-04       Impact factor: 5.911

3.  Loss of the Nuclear Pool of Ubiquitin Ligase CHIP/STUB1 in Breast Cancer Unleashes the MZF1-Cathepsin Pro-oncogenic Program.

Authors:  Haitao Luan; Bhopal Mohapatra; Timothy A Bielecki; Insha Mushtaq; Sameer Mirza; Tameka A Jennings; Robert J Clubb; Wei An; Dena Ahmed; Rokaya El-Ansari; Matthew D Storck; Nitish K Mishra; Chittibabu Guda; Yuri M Sheinin; Jane L Meza; Srikumar Raja; Emad A Rakha; Vimla Band; Hamid Band
Journal:  Cancer Res       Date:  2018-03-06       Impact factor: 12.701

4.  Breast carcinoma subtypes show different patterns of metastatic behavior.

Authors:  István Artúr Molnár; Béla Ákos Molnár; Laura Vízkeleti; Krisztina Fekete; Judit Tamás; Péter Deák; Csilla Szundi; Borbála Székely; Judit Moldvay; Stefan Vári-Kakas; Marcell A Szász; Balázs Ács; Janina Kulka; Anna-Mária Tőkés
Journal:  Virchows Arch       Date:  2017-01-19       Impact factor: 4.064

5.  BCL2 as a Subtype-Specific Prognostic Marker for Breast Cancer.

Authors:  Yong Hwa Eom; Hyung Suk Kim; Ahwon Lee; Byung Joo Song; Byung Joo Chae
Journal:  J Breast Cancer       Date:  2016-09-23       Impact factor: 3.588

6.  An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors.

Authors:  Theresa A Koleck; Catherine M Bender; Beth Z Clark; Christopher M Ryan; Puja Ghotkar; Adam Brufsky; Priscilla F McAuliffe; Priya Rastogi; Susan M Sereika; Yvette P Conley
Journal:  Breast Cancer (Dove Med Press)       Date:  2017-03-03

7.  Limited utility of tissue micro-arrays in detecting intra-tumoral heterogeneity in stem cell characteristics and tumor progression markers in breast cancer.

Authors:  Pascale Kündig; Charlotte Giesen; Hartland Jackson; Bernd Bodenmiller; Bärbel Papassotirolopus; Sandra Nicole Freiberger; Catharine Aquino; Lennart Opitz; Zsuzsanna Varga
Journal:  J Transl Med       Date:  2018-05-08       Impact factor: 5.531

8.  SOX11 promotes epithelial/mesenchymal hybrid state and alters tropism of invasive breast cancer cells.

Authors:  Erik Oliemuller; Richard Newman; Siu Man Tsang; Shane Foo; Gareth Muirhead; Farzana Noor; Syed Haider; Iskander Aurrekoetxea-Rodríguez; Maria dM Vivanco; Beatrice A Howard
Journal:  Elife       Date:  2020-09-10       Impact factor: 8.140

9.  High Expression of Tomm34 and Its Correlations With Clinicopathology in Oral Squamous Cell Carcinoma.

Authors:  Min Cai; Rukeng Tan; Yunyi Huang; Xuanyi Chen; Qingci Kong; Kaixin Guo; Meng Xu
Journal:  Pathol Oncol Res       Date:  2021-04-16       Impact factor: 3.201

Review 10.  N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer.

Authors:  Krzysztof Marek Mrozik; Orest William Blaschuk; Chee Man Cheong; Andrew Christopher William Zannettino; Kate Vandyke
Journal:  BMC Cancer       Date:  2018-10-01       Impact factor: 4.430

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.